International Journal of Open Publication and Exploration (IJOPE), ISSN: ISSN: 3006-2853
Volume 10, Issue 1, January-June, 2022, Available online at: https://ijope.com

Global Regulatory Intelligence: Leveraging Data for Faster ECTD Approvals

Sharath Reddy Venna

Senior Manager Regulatory Operations/Informatics, Leadiant Biosciences, USA

ABSTRACT

The present research investigates the utilisation of global regulatory intelligence to improve the review and approval process of electronic Common Technical Document (eCTD) submissions. With the integration of AI, automated systems, and real-time data monitoring, pharmaceutical organisations can improve the regulatory submission process, ensuring fewer submission errors occur and submission and review times shorten. Through a series of case studies showcased by utilising Astra-Zeneca and GSK, substantial improvements to approval processes were demonstrated. In the face of significant advances in regulatory intelligence and eCTD submissions, specific limitations such as the ability to accommodate changes in global regulations and regional complexity. Future research will look to standardise submission globally, while also seeking industry leaders who may develop cost-free AI options to improve regulatory compliance and operational efficiencies.

Index Terms- "Global regulatory intelligence, eCTD approval, AI-driven automation, real-time data integration, pharmaceutical compliance, regulatory challenges, data analytics, submission standardization."

INTRODUCTION

Background of the Study

Global Regulatory Approvals is a process that helps gain market authorisation for the medical and pharmaceutical products by figuring out the complex regulations and guidelines of different countries. This global regulatory approval helps to confirm the safety and efficiency offered to patients from the pharmaceutical and medical products [1]. Accurately, it can be said that, through navigating the critical regulations and guidelines of the different countries, the global regulatory approval collects the global marketing authorisations for medicinal and pharmaceutical products. The main purpose of global regulatory approval is to confirm the safety, quality and effectiveness of the pharmaceutical and medical products before marketing the products in different countries.

On the other hand, global regulatory intelligence is a possession that can collect, analyse and interpret the regulatory requirements, guidelines of government and policies that can make a positive or negative impact on a company. In order to ensure compliance and effective decision making, the pharmaceutical and medical product seller companies use this systematic process [1]. On the other hand, for submitting regulatory information for the medical and pharmaceutical products to the health authorities the companies used eCTD (electronic Common Technical Document), which is the standardized electronic format. The pharmaceutical and medical companies use eCTD because it simplifies regulatorycompliance, speeds up approvals, improves efficiency, and reduces costs. eCTD remains a critical tool for pharmaceutical companies looking to bring drugs and medical products to market faster.

Overview

This study highlights the utilization of global regulatory intelligence to manipulate data for faster eCTD applications. This global regulatory intelligence helps to manipulate the data to the International Council for Harmonisation (ICH), because the eCTD is approved and maintained by the ICH [2]. This global regulatory organisation creates technical requirements for pharmaceutical companies globally. This study will also discuss the real-life example of the pharmaceutical companies that fill out the application of eCTD. This study aims to evaluate the role of global regulatory intelligence in manipulating data for faster eCTD Approvals. This study will also discuss the challenges of eCTD and the global regulatory intelligence and its effectiveness.

Aim and Objectives

This research aims to use digital technologies and data analytics to figure out the process of how the global regulatory intelligence speeds up the eCTD approval process. 1) To discuss the role of global regulatory intelligence in the biotechnology and pharmaceutical industry. 2) To study the effect of data analytics such as automation, AI driven

perspectives and Realtime data on faster eCTD approval. 3) To figure out the regulatory challenges and opportunities in eCTD application.

Problem Statement

This study discusses the eCTD application for global regulatory approvals by ICH. The biotechnology and pharmaceutical companies face challenges in achieving global regulatory approvals within a specific time due to the complexity of regulatory requirements in launching or introducing new drugs. Disputed regulatory intelligence poses challenges in the application of eCTD, which becomes the reason for delays in approvals [3]. By following the aim of this research, find out the process by which the global regulatory intelligence can refine the eCTD application to approve on an urgent basis within a specific time. This study will also analyse the predictive models that help in reducing time in eCTD approval. This study will also find out the effect of global regulatory intelligence and enhanced data utilisation on eCTD approval.

Scope and Significance

This research will help future researchers and pharmaceutical and biotechnological companies to study the global regulatory intelligence, eCTD application, usefulness of global regulatory intelligence and the impact of global regulatory intelligence on manipulating data for the faster eCTD approvals [4]. On the other hand, this research will help the pharmaceutical companies to learn about the Faster eCTD approval process, which will help them to save their operational time and cost.

LITERATURE REVIEW

A. Role of global regulatory intelligence in the biotechnology and pharmaceutical industry

The regulatory Global intelligence helps in collecting, analysing, and interpreting the Global trends, regulated requirements and global policies that help in confirming Compliance and eCTD approval. The Pharmaceutical and Biotechnology industry needs to adopt to global regulatory intelligence because it helps to overcome rich in sure compliance and helps the management for making strategic decision in a critical and continuous changing regulatory lens this process collect analyse and interpret regulatory information which has the company to find out the Strategies and demand of the Global market and to overcome the challenges which can make obstacles for the company. The role of global regulated intelligence is insurance compliance, proactive bricks management, strategic decision making, data-driven innovation, offering competitive advantage, understanding industry trends, monitoring regulatory environment, reducing cost and time to market, facilitating decision making and identifying opportunities.

This Global regulatory intelligence helps the Pharmaceutical and biotechnological company to add the latest regulations and requirements to ensure that they fully comply with all their regulators' standards and requirements in producing the drugs and Pharmaceutical products, during marketing and manufacturing. This Global regulator intelligence also helps the pharmaceutical companies to develop an effective risk Management plan by identifying the regulatory changes and challenges. By identifying the regulatory challenges, the companies can develop their Strategies and make decisions to overcome the risk and avoid penalties for delays. On the other hand, the regulatory intelligence helps the pharmaceutical companies to understand specific regulatory requirements that depend on the regional market. In this area, the Global regulatory intelligence helps companies to figure out the market for strategy and expansion into other countries.

B. Effect of data analytics such as automation, AI-driven perspectives and real-time data on faster eCTD approval.

In order to enhance the submission of eCTD, the data analysis in hand the efficiency by improving data quality, streamlining processes and enabling better compliance through eCTD 4.0. This data analyst also helps to accelerate the regulatory reviews and approvals to get the ECTD approval within the specific time limit. Data analysis streamlines the process and improves efficiency, enhances data quality and integrity, and improves complaints and transparency. eCTD 4.0 is the Latest version of the electronic common technical document format. This updated electronic common technical format introduces multiple new features like study tagging and life cycle enhancements, which help enhance the data control and review process.

On the other hand, the latest version of the electronic common technical document enhances Data integrity and consistency by decreasing delays and the requirement for clarification during the review process. It is also observed that the automation process helps by reducing the risks of human error and also helps to ensure that the data is accurately transferred and the documents submitted by the company are properly formatted. It is also found that the updated version of the electronic common technical document offers transparent guidelines and validation criteria to the Pharmaceutical and biotechnological companies so that they can better comply with regulatory requirements, and in this way, this technology helps in reducing the risks of application errors and rejections of the applications.

C. Regulatory challenges and opportunities in eCTD application.

The global eCTD Submission process has both regulatory challenges and opportunities. This submission process phases challenges of evolving regulations and compliance, regional variations, complexity of eCTD format, transition cost, data management, limited submission experience and in anti-separating regulatory requests. On the other hand, this submission process has several opportunities, such as helping in streamlining processes, enhancing life cycle management, improving collaboration, Global harmonization, enhancing data granularity and quality, enhancing submission quality, and fostering the first regulatory submission process and automation.

It is noticed that in the eCTD application process, the regulatory requirements are continuously changing. For the companies to get updated about the latest guidelines and changes from agencies such as EMA and FDA, the Pharmaceutical and Biotechnology Companies may face challenges in identifying, analysing and retaining knowledgeable regulatory information to make effective and clear submissions. On the other hand eCTD submissions can influence the regulatory submission process to make it more efficient, accurate and faster. This application process helps to enhance life cycle management of submissions by allowing for tracking, organising and retrieval of information.

D. Case studies and examples

Case study 1: AI-driven regulatory intelligence in AstraZeneca

UK-based pharmaceutical giant AstraZeneca used AI and regulatory intelligence to reduce the process of electronic Common Technical Document (eCTD) submissions [5]. The company integrated the ability to look at historical regulatory feedback, analyse submissions, and adjust submissions based off different machine learning models that predict potential deficiencies. This proactive work resulted in a 20% reduction in the time it took to approve key drugs, or in other words market access took place faster while still keeping compliance with UK's MHRA and global regulatory standards [5].

Case study 2: GlaxoSmithKline (GSK) Real-Time Data Integration

Real-time regulatory intelligence platforms were put in place by GSK to maximise its eCTD submissions. To centralize updates of regulatory documents to a variety of agencies like MHRA and EMA, GSK used cloud-based data integration tools [6]. This allowed people to very quickly change their submission strategy, decreasing errors and resubmissions. Faster time to market with faster approval is the result, and GSK was able to accelerate the approval timelines by 15 per cent for new therapies [6].

METHODOLOGY

A. Research Design

The explanatory research design is employed to investigate how UK-based pharmaceutical companies use data for quicker electronic Common Technical Document (eCTD) approvals. It relates to the understanding of causal relationships between types of regulatory intelligence tools, data-driven decision making and approval timelines. Case studies, industry reports and interviews with industry experts will be used to gather data on how AstraZeneca, GlaxoSmithKline (GSK), for example, integrate artificial intelligence (AI), real-time analytics and automation in regulatory processes. It is the aim of the study to identify the patterns, efficiencies and best-practice strategies for using data to help in optimising eCTD submissions and alleviating regulatory bottlenecks and approval delays.

B. Data Collection

This entire research depends on both qualitative and quantitative methods of the secondary data collection process. For the qualitative methods, some academic journals, newspapers, magazines, articles, etc, have been used, and for quantitative data methods topic related graphs, charts have been used to align the entire analysis well.

C. Evaluation Metrics

The evaluation metrics of eCTD eCommerce will evaluate key performance indicators and determine how regulatory intelligence expedites eCTD approvals. Measuring the reduction in regulatory review times will provide the approval time reduction. A count of how often deficiencies are flagged will measure error rate in submissions, which represents the initial filing accuracy. Similarly, the resubmission rate will reflect the instances for which the data-based decision making calls for a revision. Adherence to the Medicine and Healthcare products Regulatory Agency (MHRA) and European Medicines Agency (EMA) guidelines will be monitored via a regulatory compliance score so that the speed does not harm compliance [7]. Finally, operational efficiency gain will quantify the AI, automation and real-time as a single data integration. Taken together, these metrics will furnish a complete account of how regulatory intelligence is employed in improving the

efficiency of eCTD approvals, expediting approval processes and maintaining compliance by UK pharmaceutical companies.

RESULTS

A. Data Presentation

Pharmaceutical companies often face threats to quantify the regulatory impact on the whole business. In leveraging data for much faster eCTD approvals, give focus to data-driven insights, automation, efficient document management and conversation with regulatory agencies, and going proactive in following regulatory strategies, such as clear communication with regulatory agencies and using advanced technology.



Figure 1: Global AI healthcare market size from 2016 to 2020

AI plays a crucial role in every department to enhance the performance of the department. On the other hand, AI plays a crucial role in developing healthcare and social assistance. AI can help with digital communications by providing patients with personalised health advice, schedule reminders, and recommended next steps. AI's capacity to support medical diagnosis also enhances the pace and precision of patient visits, resulting in quicker and more individualised treatment. Between 2019 and 2020, there was the single largest growth in a single year. In this little timeframe, the healthcare AI market grew 72.4% from $3.9 billion to $6.7 billion [14].



Figure 2: Share of AI technologies used in healthcare in the EU by 2021

According to figure 2, the use of AI in healthcare, the most common use of AI in the EU is in disease diagnosis, where over four out of ten (42%) healthcare institutions utilise AI [14]. Furthermore, within three years, nearly one in five (19%) medical organisations intend to deploy AI for disease diagnosis [14]. This indicates that over 60% of EU healthcare organisations intend to deploy AI for disease detection by the end of 2021 [14].

Figure 3: Perceived value of AI in healthcare in the US in 2021

Statistics on AI in healthcare indicate that, prior to 2021, AI's perceived value was higher than anticipated. Four out of ten (40%) respondents think the market is worth more than anticipated, according to figure 3 [14]. Just over a quarter (27%) of respondents said that it had "achieved the expected level of value", which was the second most often given response [14].

B. Findings

eCTD is the current standard format for submitting applications, amendments, supplements, and reports to regulatory agencies such as the FDA, which means that the need for paper-based submissions eliminates delays in printing, mailing, and manual processing. AI plays a crucial role in healthcare and as per the data, between 2019 and 2020, there was the single largest growth in a single year. In this little timeframe, the healthcare AI market grew 72.4% from $3.9 billion to $6.7 billion [14]. This indicates that over 60% of EU healthcare organisations intend to deploy AI for disease detection by the end of 2021 [14].

C. Case Study Outcomes

Table 1: Case Study Outcome

Case Study	Company	Outcome	Relevance to the Research
AI-driven regulatory intelligence	AstraZeneca	AI-based regulatory intelligence has decreased the eCTD duration of the acknowledgments by 20% by interpreting uncertainties [5].	This company example is relevant by showing the role of AI and ML to decrease delays, improve efficacy, and regulate submission mechanisms.
Real-Time Data Integration	GSK	Data integration in real time within the company has decreased approval times of eCTD by 15% [6].	This example is correlated with this study based on the parameters of "regulatory intelligence", highlighting functions of "data synchronization."

(Source: Self-Created)

D. Comparative Analysis

Table 2: Comparison of Literature Review Articles

Author	Aim	Findings	Gap identified
[10]	"This paper aims to show the role of AI in Pharmaceuticals."	The trend of the convergence of medical products, assisted by AI, has increased rapidly in recent years.	Lack of theoretical validation
[11]	"This article aims to determine the extent to which the available clinical development program could be assessed."	The publication of "CSR documents by the EMA" has enabled insights into timelines and "project management" areas of medications	Lack of comparative study
[12]	"This paper aims to control target product quality profiles within a defined set of quality parameters."	The smart factory of the future takes on autonomous facilities, leading to more production agility.	Lack of primary analysis
[13]	"This paper aims to identify threats during eCTD and CTD Filling Procedures."	eCTD format became necessary in regions, for the companies to conceive a unified circumstances that serve the lifecycle of "inherent submission."	Lack of primary research

(Source: Self-Created)

DISCUSSION

A. Interpretation of Result

The research findings illustrate that using global regulatory intelligence markedly increases the efficiency of eCTD approvals using AI, automation, and real-time data integration. Examples from the case studies of AstraZeneca and GSK show that both reduced approval timelines by approximately 20% and 15%, respectively, demonstrating the significant effect of data-driven regulatory intelligence. The data also show an increased trend in the use of AI in the pharmaceutical industry and investment in digital transformation for regulatory submissions. The findings show the integration of regulatory intelligence reduces submission errors, increases compliance, and reduces the length of approval timelines. However, challenges include the evolving regulatory environment and the need for standardised global submission practices to ensure speedy approvals in different countries.

B. Practical Implications

The research results present applicable implications for the goal of pharmaceutical and biotechnology companies of reducing time to market for their products. Considering the adoption of AI regulatory intelligence for eCTD, when an AI regulatory intelligence company can reduce human errors, improve compliance with Agencies that receive eCTD submissions (i.e. FDA; EMA), and reduce the time for Agency approval. A company can also strategically build a plan to support requirements, reducing the risk of a submission being rejected at any level. Improved automation will expedite documentation and life cycle management and will conserve time and resources at multiple levels.

C. Challenges and Limitations

Despite the benefits of the eCTD submission process, several challenges become apparent. The ever-changing regulations create the need for ongoing revisions to compliance strategies that can be time-consuming and costly [15]. The differences

in submission requirements by region add complexity to global approvals and inhibit organisations from standardising processes. The high start-up costs of AI and automated processes may also limit smaller companies from successful engagement with the long-term benefits [16]. The industry lacks experience with providing updates in real-time data and analysing that data with regulatory intelligence that delays submissions.

D. Recommendation

In terms of improving regulatory submission efficiency in eCTD dosing submissions, pharmaceutical companies should devote resources to AI and automation to ease eCTD approval processes. Using real-time data integration can significantly lessen errors to ensure compliance in the face of ever-changing regulations [17]. Additionally, global submission processes should be standardised across regulatory authorities to ease complexities with multi-region submissions. Additionally, they should keep regulators and the companies, and facilitate training programs, continuous training programs for regulatory teams [18]. The work with regulators like the FDA and EMA, to close the compliance knowledge gaps. Finally, SMEs can explore partnerships or cloud-based regulatory intelligence technology solutions to address cost challenges.

CONCLUSION AND FUTURE WORK

Conclusion

The study indicates the important role of global regulatory intelligence in accelerating eCTD approvals through the use of Artificial Intelligence (AI), automated processes and the integration of real-time data. The results indicate that the leveraged use of GRI promotes compliance, reduces errors, and streamlines approvals. However, there are still challenges with constantly changing regulations and large territories for compliance.

Future Research

In future studies, it would be determined standardised global submission frameworks, and explore low-cost, AI-enabled, and even no-cost options for smaller firms. Future research will also assess the longer-term consequences of automation in regulatory processes, to guarantee sustainability and overall efficiency.

REFERENCES LIST

[1]. Taskforce, H.M.A.E.M.A.J.B., 2019. Phase II Report:‘Evolving Data-Driven Regulation’. European Medicines Agency.
[2]. Fukushima, M., Austin, C., Sato, N., Maruyama, T., Navarro, E., Rocca, M., Demotes, J., Haendel, M., Volchenboum, S.L., Cowperthwaite, M. and Silverstein, J.C., 2019. The Global academic research organization network: Data sharing to cure diseases and enable learning health systems. Learning Health Systems, 3(1), p.e10073.
[3]. Patra, J.K., Shukla, A.C. and Das, G., 2020. Advances in pharmaceutical biotechnology. Recent progress and future applications.
[4]. Milanesi, M., Runfola, A. and Guercini, S., 2020. Pharmaceutical industry riding the wave of sustainability: Review and opportunities for future research. Journal of cleaner production, 261, p.121204.
[5]. Astrazeneca.com, 2020, Full-year and Q4 2019 results, Available at:https://www.astrazeneca.com/content/dam/az/PDF/2019/full-year/Full-year_and_Q4_2019_results_presentation.pdf [Accessed on: 17th January 2020]
[6]. Gsk.com, 2020, Annual Report 2020, Available at: https://www.gsk.com/media/6662/annual-report-2020.pdf [Accessed on: 16 January 2020]
[7]. Jha, D., Jain, V., Sharma, B., Kant, A. and Garlapati, V.K., 2017. Microalgae-based pharmaceuticals and nutraceuticals: an emerging field with immense market potential. ChemBioEng Reviews, 4(4), pp.257-272.
[8]. Freyrsolutions.com, 2022, What is Regulatory Intelligence?, Available at: https://www.freyrsolutions.com/what-is-regulatory-intelligence [Accessed on: 17th February 2022]
[9]. Biomapas.com, 2022, The Role of Regulatory Intelligence in Pharmacovigilance, Available at: https://www.biomapas.com/the-role-of-regulatory-intelligence-in-pharmacovigilance/ [Accessed on: 27th January 2022]
[10]. Opderbeck, D.W., 2019. Artificial intelligence in pharmaceuticals, biologics, and medical devices: present and future regulatory models. Fordham L. Rev., 88, p.553.
[11]. Lehmann, S., Allard, R. and Boehler, Y.B., 2019. The European Medicines Agency Clinical Data Website Enables Insights Into Clinical Development Timelines And Strategy. Open Access Journal of Clinical Trials, pp.37-56.
[12]. Arden, N.S., Fisher, A.C., Tyner, K., Yu, L.X., Lee, S.L. and Kopcha, M., 2021. Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future. International journal of pharmaceutics, 602, p.120554.

[13]. Ahammad, N., Reddy, N., Nagabhushanam, M.V. and Ramakrishna, B., 2019. Challenges Faced During eCTD and CTD Filling Procedures for USFDA and Canada. Journal of Drug Delivery and Therapeutics, 9, pp.673-679.
[14]. Aiprm.com, 2020, ai-in-healthcare Available at:https://www.aiprm.com/ai-in-healthcare-statistics/ [Accessed on: 27 March 2020]
[15]. Gantzias, G., 2020. Dynamics of public interest in artificial intelligence:'Business intelligence culture'and global regulation in the digital era. In The Palgrave handbook of corporate sustainability in the digital era (pp. 259-281). Cham: Springer International Publishing.
[16]. Butcher, J. and Beridze, I., 2019. What is the state of artificial intelligence governance globally?. The RUSI Journal, 164(5-6), pp.88-96.
[17]. Chintale P: Optimizing data governance and privacy in Fintech: leveraging Microsoft Azure hybrid cloud solutions. Int J Innov Eng Res. 2022, 11:
[18]. INNOVATIONS IN AZURE MICROSERVICES FOR DEVELOPING SCALABLE", int. J. Eng. Res. Sci. Tech., vol. 17, no. 2, pp. 76–85, May 2021, doi: 10.62643/
[19]. "Intelligent Process Automation in S/4 HANA FICO: A Machine Learning Approach ", IJIEE, vol. 10, no. 2, pp. 57–70, Feb. 2020, doi: 10.48047/aqtbk646.
[20]. Lamberti, M.J., Wilkinson, M., Donzanti, B.A., Wohlhieter, G.E., Parikh, S., Wilkins, R.G. and Getz, K., 2019. A study on the application and use of artificial intelligence to support drug development. Clinical therapeutics, 41(8), pp.1414-1426.
[21]. He, J., Baxter, S.L., Xu, J., Xu, J., Zhou, X. and Zhang, K., 2019. The practical implementation of artificial intelligence technologies in medicine. Nature medicine, 25(1), pp.30-36.